Jeff Lamothe is President and Chief Executive Officer of Aptevo Therapeutics and a member of the Board of Directors. He leads the development and execution of corporate strategy as Aptevo advances differentiated immuno-oncology therapies built on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms.

Jeff brings deep executive leadership experience to the role, including more than 20 years serving in C-suite positions as Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer across multiple industries.

As a founding member of Aptevo’s leadership team, Jeff progressed from Chief Financial Officer to Chief Operating Officer and now Chief Executive Officer, bringing financial discipline, operational leadership, and strategic vision. As COO, he oversaw Clinical, Research and Development, Quality, Manufacturing, and Operations, advancing multiple programs in parallel. Earlier, as CFO, he led Finance, Business Development, Investor Relations, and Information Technology, helping to establish the strategic and financial framework that supported the company’s growth. Prior to joining Aptevo, he served as Vice President Finance, Biosciences Division at Emergent BioSolutions following its acquisition of Cangene Corporation, where he was Chief Financial Officer.